Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are recommended for glycaemic management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP‐1RA, has recently been approved for clinical use, based on the results of the randomized, Phase 3a Peptide InnOvatioN for Early d...

Descripción completa

Detalles Bibliográficos
Autores principales: Thethi, Tina K., Pratley, Richard, Meier, Juris J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384149/
https://www.ncbi.nlm.nih.gov/pubmed/32267058
http://dx.doi.org/10.1111/dom.14054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384149/
https://www.ncbi.nlm.nih.gov/pubmed/32267058
http://dx.doi.org/10.1111/dom.14054

Ejemplares similares